SARS-CoV-2 Spike and Antibodies
Structural biologists are revealing the many ways that antibodies recognize SARS-CoV-2
Structures of antibody Fab fragments (yellow) bound to SARS-CoV-2 spike protein (magenta). All structures include the variable domains of the antibodies, and some of the structures also include constant domains.Download high quality TIFF image
The structural biology community has mobilized its forces in the fight against the COVID-19 pandemic. Laboratories around the world have studied virtually every aspect of the virus, looking for weak points that can be targeted to fight infection. The spike protein
has been a major focus of this effort, because it plays an essential role in the viral life cycle, and it is the major target for protection by our immune system. In the year or so since this virus emerged, hundreds of structures of the spike protein have been determined, revealing details of its flexibility and interaction with the cellular receptor ACE2, and the way the immune system blocks it with neutralizing antibodies.
A small selection of spike-antibody structures is shown here, highlighting the some of the many ways that antibodies recognize the protein. Four of these antibodies were isolated from patients infected with SARS-CoV-2. The three at the top recognize the receptor-binding domain of the spike, but in different ways. Antibody fragment C002 (PDB ID 7k8t
) binds to the site that recognizes ACE2 and binds to receptor-binding domains in both the active up and inactive down conformations. S2M11 (PDB ID 7k43
) binds in a different way, locking the receptor-binding domains in the down position, and EY6A (PDB ID 6zdh
) binds further down the domain. The two antibodies at the bottom show entirely different modes of binding. 4A8 (PDB ID 7c2l
) binds to an adjacent domain but still neutralizes the action of the spike. 2G12 (PDB ID 7l06
) is an unusual antibody elicited by infection with HIV-1, which also binds to SARS-CoV-2 but doesn't neutralize it. It contains two domain-swapped antibodies that together recognize sugars on the spike surface.
Of course, the major goal of all this work is to develop new ways to protect people from infection and to treat infected individuals. One major insight that is driving much of this work is the diversity of ways that antibodies recognize the spike. This insight opens the door to combination therapies, where people are treated with a cocktail of antibodies, or vaccines are designed to elicit many types of antibodies. By targeting the spike in many ways, combination approaches may help control the emergence of resistant strains. As seen in HIV-1 therapy, it is far more difficult for the virus to evolve resistance if has to mutate to evade multiple drugs at the same time.
Researchers are also exploring approaches to engineer smaller forms of antibodies, termed nanobodies,
for use in treatment of the disease. Two examples are shown here. The Ty1 (PDB ID 6zxn
) single-chain antibody was discovered by immunizing alpacas with the viral spike. It binds to the receptor-binding domain in the up and down conformations, and blocks binding to the ACE2 receptor. The nanobody mNb6 (PDB ID 7kkl
) was selected from a library of synthetic nanobodies, and then optimized by making many small changes in the portions that interact with the spike and selecting the tightest binders. It binds to the receptor-binding domains in the inactive down position.
Exploring the Structure
SARS-CoV-2 Spike and Antibody Cocktails
Structural biologists are now exploring how cocktails of antibodies could work together to block the virus. Two examples are shown here. On the left, from PDB ID 7cwu, P17 blocks the receptor-binding site and FC05 binds to the N-terminal domain. On the right, from PDB ID 7cwn, P17 is combined with H014, which binds to the lower site on the receptor-binding domain. To explore these structures in more detail, click on the image for an interactive JSmol.
Topics for Further Discussion
- Many additional structures of antibodies bound to spike and to spike domains, as well as structures of antibodies and spike by themselves, can be found in the PDB archive.
- While you’re exploring these structures, you need to use some imagination. As noted in the first figure, all of these structures include the variable domains of the antibodies, but only some modeled coordinates for the constant domains. In addition, the membrane-spanning portions of the spike are missing, and typically only the first few sugars are included at the many sites of glycosylation.
Related PDB-101 Resources
- 7k8t: Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.A., Esswein, S.R., Gristick, H.B., Malyutin, A.G., Sharaf, N.G., Huey-Tubman, K.E., Lee, Y.E., Robbiani, D.F., Nussenzweig, M.C., West Jr., A.P., Bjorkman, P.J. (2020) SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588: 682-687
- 7c2l: Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., Chen, Z., Guo, Y., Zhang, J., Li, Y., Song, X., Chen, Y., Xia, L., Fu, L., Hou, L., Xu, J., Yu, C., Li, J., Zhou, Q., Chen, W. (2020) A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369: 650-655
- 6zxn: Hanke, L., Vidakovics Perez, L., Sheward, D.J., Das, H., Schulte, T., Moliner-Morro, A., Corcoran, M., Achour, A., Karlsson Hedestam, G.B., Hallberg, B.M., Murrell, B., McInerney, G.M. (2020) An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun 11: 4420-4420
- 7kkl: Schoof, M., Faust, B., Saunders, R.A., Sangwan, S., Rezelj, V., Hoppe, N., Boone, M., Billesbolle, C.B., Puchades, C., Azumaya, C.M., Kratochvil, H.T., Zimanyi, M., Deshpande, I., Liang, J., Dickinson, S., Nguyen, H.C., Chio, C.M., Merz, G.E., Thompson, M.C., Diwanji, D., Schaefer, K., Anand, A.A., Dobzinski, N., Zha, B.S., Simoneau, C.R., Leon, K., White, K.M., Chio, U.S., Gupta, M., Jin, M., Li, F., Liu, Y., Zhang, K., Bulkley, D., Sun, M., Smith, A.M., Rizo, A.N., Moss, F., Brilot, A.F., Pourmal, S., Trenker, R., Pospiech, T., Gupta, S., Barsi-Rhyne, B., Belyy, V., Barile-Hill, A.W., Nock, S., Liu, Y., Krogan, N.J., Ralston, C.Y., Swaney, D.L., Garcia-Sastre, A., Ott, M., Vignuzzi, M., QCRG Structural Biology Consortium, Walter, P., Manglik, A. (2020) An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370: 1473-1479
- 7k43: Tortorici, M.A., Beltramello, M., Lempp, F.A., Pinto, D., Dang, H.V., Rosen, L.E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., Zatta, F., De Marco, A., Guarino, B., Bianchi, S., Lauron, E.J., Tucker, H., Zhou, J., Peter, A., Havenar-Daughton, C., Wojcechowskyj, J.A., Case, J.B., Chen, R.E., Kaiser, H., Montiel-Ruiz, M., Meury, M., Czudnochowski, N., Spreafico, R., Dillen, J., Ng, C., Sprugasci, N., Culap, K., Benigni, F., Abdelnabi, R., Foo, S.C., Schmid, M.A., Cameroni, E., Riva, A., Gabrieli, A., Galli, M., Pizzuto, M.S., Neyts, J., Diamond, M.S., Virgin, H.W., Snell, G., Corti, D., Fink, K., Veesler, D. (2020) Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370: 950-957
- 6zdh: Zhou, D., Duyvesteyn, H.M.E., Chen, C.P., Huang, C.G., Chen, T.H., Shih, S.R., Lin, Y.C., Cheng, C.Y., Cheng, S.H., Huang, Y.C., Lin, T.Y., Ma, C., Huo, J., Carrique, L., Malinauskas, T., Ruza, R.R., Shah, P.N.M., Tan, T.K., Rijal, P., Donat, R.F., Godwin, K., Buttigieg, K.R., Tree, J.A., Radecke, J., Paterson, N.G., Supasa, P., Mongkolsapaya, J., Screaton, G.R., Carroll, M.W., Gilbert-Jaramillo, J., Knight, M.L., James, W., Owens, R.J., Naismith, J.H., Townsend, A.R., Fry, E.E., Zhao, Y., Ren, J., Stuart, D.I., Huang, K.A. (2020) Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27: 950-958
- 7cws: Wang, N., Sun, Y., Feng, R., Wang, Y., Guo, Y., Zhang, L., Deng, Y.Q., Wang, L., Cui, Z., Cao, L., Zhang, Y.J., Li, W., Zhu, F.C., Qin, C.F., Wang, X. (2021) Structure-based development of human antibody cocktails against SARS-CoV-2. Cell Res 31: 101-103
- 7cwn: Yao, H., Sun, Y., Deng, Y.Q., Wang, N., Tan, Y., Zhang, N.N., Li, X.F., Kong, C., Xu, Y.P., Chen, Q., Cao, T.S., Zhao, H., Yan, X., Cao, L., Lv, Z., Zhu, D., Feng, R., Wu, N., Zhang, W., Hu, Y., Chen, K., Zhang, R.R., Lv, Q., Sun, S., Zhou, Y., Yan, R., Yang, G., Sun, X., Liu, C., Lu, X., Cheng, L., Qiu, H., Huang, X.Y., Weng, T., Shi, D., Jiang, W., Shao, J., Wang, L., Zhang, J., Jiang, T., Lang, G., Qin, C.F., Li, L., Wang, X. (2021) Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Cell Res 31: 25-36
- 7l06: Acharya, P., Williams, W., Henderson, R., Janowska, K., Manne, K., Parks, R., Deyton, M., Sprenz, J., Stalls, V., Kopp, M., Mansouri, K., Edwards, R.J., Meyerhoff, R.R., Oguin, T., Sempowski, G., Saunders, K., Haynes, B.F. (2020) Biorxiv DOI: 10.1101/2020.06.30.178897
April 2021, David Goodsell